Dr. Lal Path Labs Ltd. CC-Feb26.pdf · 2026-01-30
My first question is on the extent of utilization of both the Mumbai and Bangalore reference labs. Given that we continue to open about 600 to 800 collection centers annually with greater focus on the high -growth North markets, ex of Delhi, how do you plan to ramp up the utilization of these 2 specific reference labs?
That is helpful, sir. I will just ask one more question. Given that we follow a revenue sharing arrangement with our franchise network and that in markets, ex. of Delhi, we end up sharing more than 25% of our revenue with the network, do you foresee incremental margin dilution given franchisee -led growth? If not, how much more bandwidth do we have on expanding our EBITDA margins via process efficiencies and leverage, given that all of our growth has been volume and price led at least over the last 2 years?